First line treatment for chronic lymphocytic leukemia - Industry News

Enlai News

联系我们

Outbound Sales&Marketing

Cynthia

Tel: +86 2864841719

Mobile: +86 17390183901 (English)

Skype/Wechat:+86 18716376478

Email: ycling@enlaibio.com

Mr. Yang

Tel: +86 2884871826

Mobile: +86 13908183771

Email: yangcx@enlaibio.com

Amy

Tel： 028-84841969

Mobile：15884568590

QQ：551604319

Email：Amy@enlaibio.com

Bob
Tel：18980456393
Email：edison@enlaibio.com
QQ:3054240163

Daisy
Tel：18314163848
Email：daisy@enlaibio.com
QQ：2065506070

Your current location:Homepage >

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

The typical cost of ibrutinib in the United States is about $148,000 a year.

In China, Ibrutinib was added to the Chinese Pharmaceutical Benefits Scheme in 2018.

In the previous:None
The next article:From Poverty to Harvard Postdoc